• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Siemens Healthineers and Braunschweig Municipal Hospital enter into strategic technology partnership

, 26 August 2020/in E-News /by 3wmedia

Braunschweig Municipal Hospital and Siemens Healthineers are breaking new ground through an innovative medical technology partnership. Together, they have entered into a long-term Asset Management Services (AMS) contract. Braunschweig Municipal Hospital is one of the largest hospitals in northern Germany, with 1,499 beds and 38 clinics and institutes. Siemens Healthineers will assume responsibility for supplying and maintaining all initial and replacement equipment in the areas of radiology, radiotherapy and nuclear medicine. The partnership also includes strategic and operational consulting services to drive continuous improvement initiatives over time. On October 23, in Braunschweig, the parties signed a ten-year contract with a five-year extension option.
“The primary goal of this technology partnership is to assure high-quality and cost-effective medical care for our patients through first-class diagnostic radiological, surgical and radiotherapy services”, explains Ulrich Markurth, mayor of Braunschweig and chairman of the hospital’s supervisory board.
“We are very pleased to be able to contribute as a technology partner in the coming years to further improve the quality of patient care at the Braunschweig Municipal Hospital and its performance capability,” says Dr. Stefan Schaller, head of Siemens Healthineers in Germany. “In addition to the provision of innovative medical technology systems, we support the Braunschweig Municipal Hospital in planning new buildings and optimizing workflows in radiology, cardiology and the emergency department as well as in all steps towards the digitization of healthcare. This holistic package provides the hospital with security of planning, budget certainty and future reliability over the entire duration of the project.”
Matthias Platsch, President of Siemens Healthineers Services adds: “We are delighted to have been chosen as a technology partner for the Braunschweig Municipal Hospital and we are both proud and humbled by the vote of confidence that this important healthcare provider has placed in our new services portfolio. In this, Siemens Healthineers’ first asset management services partnership in Germany, we will combine the strength of our innovative product portfolio with the forward-looking business approach of our enterprise services to help deliver best-value clinical outcomes for patients. Together with the Braunschweig Municipal Hospital, we will transform healthcare delivery by leveraging our combined expertise in established and new care models. With a fresh look at the design and operation of the facility we will significantly improve the patient experience, and the new technologies we will deploy will enable more efficient and more precise clinical diagnosis. We are very excited to play such a role in the future of healthcare in Braunschweig.”
Hospital CEO Dr. Andreas Goepfert explains that the award of the contract for this technology partnership, including the vendor-neutral procurement and management of around 50 new systems (ranging from magnetic resonance and computed tomography, to angiography, X-ray, nuclear medicine and radiotherapy machines) is the result of a Europe-wide call for tenders via an initial selection process and a competitive dialogue. The fundamental premise is that this innovative, end-to-end partnership model – for procurement and management, in particular – will generate savings for the hospital compared to a series of individual, reactive calls for tender.
As a consequence, Siemens Healthineers will be responsible for procurement, installation, maintenance, servicing, an innovation guarantee (through updates and upgrades), and an availability guarantee for all devices. The long-term technology roadmap takes into consideration the hospital’s strategic orientation, especially its current plan to concentrate the hospital at two locations. A Syngo.via Enterprise solution will also give the hospital access to all Siemens Healthineers’ software applications, enabling it to stay at the forefront of digital innovation.
 “The technology partnership in the area of radiology will bring together the heterogeneous imaging device landscape and IT in our radiology department at Braunschweig Municipal Hospital,” forecasts its medical director, Dr. Thomas Bartkiewicz. “That ensures we always stay at the forefront of innovation in diagnostic imaging and imaging-based treatment, while ensuring radiation exposure for patients and employees is kept to a minimum.” Complex interfaces will be removed and the clinical staff will find their day-to-day work routines become noticeably simpler. Nursing director Ulrich Heller adds: “Different operating processes from various device manufacturers will be reduced to a single standardized system.” This will speed up workflows and improve quality of care at the same time. In addition, maintenance plans and contracts that were not previously coordinated will be combined as part of an optimized programme in the future. The result will be a sustainable reduction in maintenance costs.
The ‘Braunschweig Model’ for a technology partnership enables the hospital to respond flexibly to changing requirements and future device needs due to a separate ‘innovation budget’. This includes possible changes in both the scope and the timing of procurement throughout the entire term of the partnership. The fixed quarterly payment fee also provides the hospital with budgetary certainty for the contract duration.
“The technology partnership guarantees predictability of costs whilst providing security of investments in the fields of radiology, radiotherapy and nuclear medicine,” says hospital CEO Goepfert. The long-term technology partnership will enable the hospital to benefit from future technological advances in radiology, including innovative algorithms to improve image reading and computer-assisted diagnostic modules. This will ensure high-quality and cost-effective patient care for the long term.
The AMS also encompasses a number of flagship projects in which the two partners will work closely together in the future. For example, Siemens Healthineers will contribute the know-how in the area of molecular diagnostics built up by its company NEO New Oncology GmbH. Thanks to genome analyses of tumour tissue performed by NEO New Oncology, Braunschweig Municipal Hospital will be able to create customized, targeted treatment recommendations that will facilitate highly promising precision medical treatment for cancer patients. www.siemens.com/healthineers

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:36:53Siemens Healthineers and Braunschweig Municipal Hospital enter into strategic technology partnership

Self-powered paper-based ‘SPEDs’ may lead to new medical-diagnostic tools

, 26 August 2020/in E-News /by 3wmedia

A new medical-diagnostic device made out of paper detects biomarkers and identifies diseases by performing electrochemical analyses – powered only by the user’s touch – and reads out the color-coded test results, making it easy for non-experts to understand.
“You could consider this a portable laboratory that is just completely made out of paper, is inexpensive and can be disposed of through incineration,” said Ramses V. Martinez, an assistant professor of industrial and biomedical engineering at Purdue University. “We hope these devices will serve untrained people located in remote villages or military bases to test for a variety of diseases without requiring any source of electricity, clean water, or additional equipment.”
The self-powered, paper-based electrochemical devices, or SPEDs, are designed for sensitive diagnostics at the “point-of-care,” or when care is delivered to patients, in regions where the public has limited access to resources or sophisticated medical equipment.
The test is initiated by placing a pinprick of blood in a circular feature on the device, which is less than two-inches square. SPEDs also contain “self-pipetting test zones” that can be dipped into a sample instead of using a finger-prick test. The top layer of the SPED is fabricated using untreated cellulose paper with patterned hydrophobic “domains” that define channels that wick up blood samples for testing. These “microfluidic channels” allow for accurate assays that change colour to indicate specific testing results. A machine-vision diagnostic application also was created to automatically identify and quantify each of these “colorimetric” tests from a digital image of the SPED, perhaps taken with a cellphone, to provide fast diagnostic results to the user and to facilitate remote-expert consultation.
The bottom layer of the SPED is a “triboelectric generator,” or TEG, which generates the electric current necessary to run the diagnostic test simply by rubbing or pressing it. The researchers also designed an inexpensive handheld device called a potentiostat, which is easily plugged into the SPED to automate the diagnostic tests so that they can be performed by untrained users. The battery powering the potentiostat can be recharged using the TEG built into the SPEDs. “To our knowledge, this work reports the first self-powered, paperbased devices capable of performing rapid, accurate, and sensitive electrochemical assays in combination with a low-cost, portable potentiostat that can be recharged using a paper-based TEG,” Martinez said.

Purdue University https://www.purdue.edu/newsroom/releases/2017/Q3/self-powered-paper-based-speds-may-lead-to-new-medical-diagnostic-tools.html

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:37:01Self-powered paper-based ‘SPEDs’ may lead to new medical-diagnostic tools

New method for organ transplant monitoring promises better care for patients

, 26 August 2020/in E-News /by 3wmedia

Using a combination of DNA sequencing and computer science techniques, a team of researchers has developed a new method for monitoring the health of organ transplant patients – one that promises to provide life-saving clues to diagnose organ rejection at an early stage.
More than 180,000 people live with organ transplants in the U.S., and many undergo costly and risky biopsies to determine if their body is accepting or rejecting an organ. An alternate method demonstrated by Iwijn De Vlaminck, who is also a senior author of the current study, found that cell-free DNA (cfDNA), essentially fragments of dead cells derived from an organ, can be detected in a patient’s bloodstream and used as a proxy for the organ’s health. The more cfDNA that is discovered, the greater the likelihood the organ is failing. But without knowing the donor’s DNA – which is often the case – doctors have no reference to identify the cfDNA.
But now a research team from Cornell and Stanford University has demonstrated a method for identifying cfDNA without the donor. To address the issue, Eilon Sharon, postdoctoral researcher with Jonathan Pritchard, and colleagues worked to develop a computer algorithm that estimates the donor-derived cfDNA and can predict heart and lung rejection with an accuracy similar to that in cases where donor information is available. Their work also details a refined algorithm to address closely related recipients and donors, a scenario that is common in bone marrow and kidney transplantations.
The algorithm uses publicly available genotypes and techniques of relationship inference to model which cfDNA fragments are most likely from the organ. "Specifically, the model infers the donor’s most probable ancestral population and accounts for close relationship by detecting DNA segments that are identical due to close descent," said Sharon, adding that the phenomenon is known as "identity by descent."
The findings alleviate a major barrier to using cfDNA detection – also known as genome transplant dynamics – instead of biopsies, and researchers hope the computer science-based method will help save lives. Accurate monitoring of organ health is essential to a patient’s long-term survival; currently, the median life expectancy for a heart transplant patient is around 11 years, and only 5.3 years for recipients of lungs.

EurekAlert
www.eurekalert.org/pub_releases/2017-08/p-nmf072717.php

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:37:08New method for organ transplant monitoring promises better care for patients

Hormone therapy in the menopause transition did not increase stroke risk

, 26 August 2020/in E-News /by 3wmedia

Postmenopausal hormone therapy is not associated with increased risk of stroke, provided that it is started early, according to a report from Karolinska Institutet.
Roughly three in ten women in the menopause transition are afflicted by symptoms that seriously affect their wellbeing, such as hot flushes, dry mucosa and insomnia. However, although the symptoms can be treated effectively with female sex hormones, prescriptions have been low over the past 15 years as researchers have demonstrated a link between such therapy and an increased risk of certain diseases, including stroke.
There is still, however, a need for more research on the issue, as the risk can be influenced by the time of the treatment and other factors, reasons Karin Leander, researcher at Karolinska Institutet’s Institute of Environmental Medicine.
“New research shows us that hormone therapy actually has a positive effect on blood vessels if initiated early on in the menopause, but not if initiated late,” says Dr Leander. “So there was reason to re-examine whether hormone therapy is linked to the risk of stroke, taking, of course, the time of administering into consideration.”
Dr Leander and her colleagues have now analysed data on postmenopausal hormone therapy from five Swedish cohort studies covering a total of 88,914 women, combined with data from national registries on diagnoses and causes of death during a follow-up period.
Hormone therapy was not linked to increased risk of stroke (ischemic and hemorrhagic stroke combined) if the therapy was initiated within five years of menopausal onset, regardless of means of administration (oral, via the skin or vaginal), type of therapy (combination or estrogen only), active substance and treatment duration.
In sub-analyses, however, there was an observable increase in risk for hemorrhagic stroke (the less common form) if the therapy contained the active substance conjugated equine estrogens. Drugs containing estradiol, on the other hand, were not associated with a higher risk. A higher risk was also seen for both ischemic and hemorrhagic stroke if the treatment was initiated later than five years after the onset of menopause and contained conjugated equine estrogens.
“The risk of stroke seems virtually eradicable if treatment commences early, but it’s naturally important to take account of the increase in risk that exists under certain circumstances,” says Dr Leander. “These results provide doctors with a better scientific base on which to take decisions on treatment for menopausal symptoms.”
Karolinska Institutehttps://tinyurl.com/ycqy6tdg

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:36:47Hormone therapy in the menopause transition did not increase stroke risk

Expanding point-of-care disease diagnostics with ultrasound

, 26 August 2020/in E-News /by 3wmedia

Fast, accurate and inexpensive medical tests in a doctor’s office are only possible for some conditions. To create new in-office diagnostics for additional diseases, researchers report a new technique that uses ultrasound to concentrate fluorescently-labelled disease biomarkers otherwise impossible to detect with current equipment in an office setting. The markers’ signal could someday be analysed via a smartphone app.
Ultrasound is a safe, non-invasive, inexpensive and portable technique best known for monitoring pregnancies. But these high-frequency acoustic waves can also be used to gently handle blood components, cells and protein crystals at the microscopic level. With an eye toward point-of-care diagnostic applications, Tony Huang, Zhangming Mao and colleagues wanted to harness these sound waves to help detect even smaller particles and biomarkers for diseases such as cancer that often require special laboratory equipment to detect.
The researchers developed an acoustofluidic chip that, though vibrations, can form a streaming vortex inside a tiny glass capillary tube using a minimal amount of energy. Testing showed that the vortex could force nanoparticles ranging in diameter from 80 to 500 nanometers to swirl into the centre of the capillary. The nanoparticles captured biomarkers labelled with a fluorescent tag, concentrating them in the capillary to boost their signal. This increased brightness could make the signal readable with a smartphone camera.

American Chemical Societyhttp://tinyurl.com/yd5ltoul

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:36:56Expanding point-of-care disease diagnostics with ultrasound

New imaging technique aims to ensure surgeons completely remove cancer

, 26 August 2020/in E-News /by 3wmedia

Of the quarter- million women diagnosed with breast cancer every year in the United States, about 180,000 undergo surgery to remove the cancerous tissue while preserving as much healthy breast tissue as possible.
However, there’s no accurate method to tell during surgery whether all of the cancerous tissue has been successfully removed. The gold-standard analysis takes a day or more, much too long for a surgeon to wait before wrapping up an operation. As a result, about a quarter of women who undergo lumpectomies receive word later that they will need a second surgery because a portion of the tumour was left behind.
Now, researchers at Washington University School of Medicine in St. Louis and California Institute of Technology report that they have developed a technology to scan a tumour sample and produce images detailed and accurate enough to be used to check whether a tumour has been completely removed.
Called photoacoustic imaging, the new technology takes less time than standard analysis techniques. But more work is needed before it is fast enough to be used during an operation.
"This is a proof of concept that we can use photoacoustic imaging on breast tissue and get images that look similar to traditional staining methods without any sort of tissue processing," said Deborah Novack, MD, PhD, an associate professor of medicine, and of pathology and immunology, and a co-senior author on the study.
The researchers are working on improvements that they expect will bring the time needed to scan a specimen down to 10 minutes, fast enough to be used during an operation. The current gold-standard method of analysis, which is based on preserving the tissue and then staining it to make the cells easier to see, hasn’t gotten any faster since it was first developed in the mid-20th century.
To speed up the process, the researchers took advantage of a phenomenon known as the photoacoustic effect. When a beam of light of the right wavelength hits a molecule, some of the energy is absorbed and then released as sound in the ultrasound range. These sound waves can be detected and used to create an image.
"All molecules absorb light at some wavelength," said co-senior author Lihong Wang, PhD, who conducted the work when he was a professor of biomedical engineering at Washington University’s School of Engineering & Applied Science. He is now at Caltech. "This is what makes photoacoustic imaging so powerful. Essentially, you can see any molecule, provided you have the ability to produce light of any wavelength. None of the other imaging technologies can do that. Ultrasound will not do that. X-rays will not do that. Light is the only tool that allows us to provide biochemical information."
The researchers tested their technique by scanning slices of tumours removed from three breast cancer patients. For comparison, they also stained each specimen according to standard procedures.
The photoacoustic image matched the stained samples in all key features. The architecture of the tissue and subcellular detail such as the size of nuclei were clearly visible.
"It’s the pattern of cells – their growth pattern, their size, their relationship to one another – that tells us if this is normal tissue or something malignant," Novack said. "Overall, the photoacoustic images had a lot of the same features that we see with standard staining, which means we can use the same criteria to interpret the photoacoustic imaging. We don’t have to come up with new criteria."
Having established that photoacoustic techniques can produce usable images, the researchers are working on reducing the scanning time.

Siteman Cancer Center http://tinyurl.com/y87u35l5

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:37:03New imaging technique aims to ensure surgeons completely remove cancer

Continuous EEG better at identifying oxygen-deprived newborns most at risk

, 26 August 2020/in E-News /by 3wmedia

Continuously recording the brain’s electrical signals and examining how those impulses evolve over time is a more reliable way to identify infants at risk for brain injury, compared with doing snapshot evaluations, according to a prospective cohort study led by Children’s National Health System research-clinicians.
Amplitude-integrated electroencephalogram (aEEG) is a bedside tool that involves attaching tiny electrodes to the newborn’s scalp to permit clinicians to monitor the complex electrical activity of the child’s brain over time. It’s a positive sign when an aEEG shows babies beginning to sleep and wake normally by the time they are 3 days old. Conversely, severely abnormal aEEG readings in the first days of life predict poor outcomes.
The Children’s team used aEEG with infants born with hypoxic-ischemic encephalopathy (HIE), one of the most severe complications that can affect full-term infants. During pregnancy, birth or shortly after birth, a hypoxic-ischemic event can occur that impedes blood flow and oxygen delivery to the brain, resulting in destruction of brain tissue. Cooling (therapeutic hypothermia) is now standard for newborns with HIE in order to stave off life-long consequences, but deaths and neurodevelopmental disability still can occur.
“We know whole-body cooling─or lowering the body’s temperature by about 3 degrees Celsius─can help vulnerable newborns survive and can protect their brains from suffering profound injuries,” says An N. Massaro, M.D., a Children’s National neonatologist and senior author of the study. “What we were trying to determine with this study is whether evaluating the pattern of evolution of the aEEG as a whole provides more information compared with looking at snapshots in time.”
Eighty infants undergoing therapeutic cooling who met the inclusion criteria were enrolled in the five-year study, one of the largest such studies to date. The babies weighed more than 1,800 grams and were older than 35 weeks’ gestational age at birth, and either needed prolonged resuscitation after birth or had low APGAR scores─ a measure of how well newborns fare outside the womb. Continuous recordings of EEG data occurred from the time of admission up to 12 hours after the infants temperatures were raised to normal and aEEG tracings were calculated.
After the therapeutic cooling blankets were removed, the infants underwent at least one magnetic resonance imaging (MRI) scan prior to discharge. During the routine follow-up check at about 18 months of age, the HIE survivors’ cognitive and motor skills were assessed using validated instruments.
Fifty-six of the infants in the study had favourable outcomes. Twenty-four infants had adverse outcomes, including 15 with severe brain injury detected by MRI and nine infants who died. These children had lower APGAR scores at five minutes, and were more likely to have severe HIE and to have experienced more frequent seizures.
“Infants whose aEEG abnormalities do not improve were at increased risk: Infants who do not reach a discontinuous background pattern by 15.5 hours of life, achieve cycling by 45.5 hours after birth and who fail to achieve continuous normal voltage by 78 hours after birth are most at risk for adverse outcomes,” Dr. Massaro says. “In addition to defining worrisome trends, we found that overall assessment of continuous aEEG readings through the course of hypothermia treatment provide the most meaningful predictive power. This means we can speak with families at the bedside with more confidence about their child’s outcomes after the infant undergoes cooling therapy.”
Children’s National Health System
childrensnational.org/news-and-events/childrens-newsroom/2017/continuous-eeg-better-at-identifying-oxygen-deprived-newborns-most-at-risk

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:36:50Continuous EEG better at identifying oxygen-deprived newborns most at risk

Transdermal estradiol shows promise in treating and preventing perimenopausal depression

, 26 August 2020/in E-News /by 3wmedia

It’s no secret that depression is a commonly reported symptom of the menopause transition. Several small trials have previously suggested that transdermal estradiol therapy (i.e., an estrogen patch) effectivelytreats perimenopausal depression. But this is the first study to examine its effectiveness in preventing the onset of perimenopausal depression among women who were previously not depressed. Estradiol is the primary estrogen (female sex hormone) that is produced during a woman’s reproductive years, impacting reproduction as well as sexual function.
A 12-month intervention conducted by Drs. David Rubinow and Susan Girdler and their team at the University of North Carolina at Chapel Hill demonstrated that transdermal estradiol was more effective than placebo in maintaining a more positive mood and in preventing the emergence of clinically significant depression particularly among women in the early menopause transition (as opposed to women in the late menopause transition or postmenopausal period). The effectiveness of treatment on mood was also stronger in women who reported a greater number of stressful events in the six months preceding enrollment.
“This study suggests that the stabilization of fluctuating estradiol levels, which are characteristic of the menopause transition, with transdermal estradiol may represent one option for preventing the development of depressive symptoms in the menopause transition,” says Dr. Jennifer Gordon, a lead researcher on the study team from the University of Regina in Saskatchewan, Canada.
“An interesting finding in this study is the impact of recent life events, which signals that healthcare providers may need to inquire about such events when determining whether or not to prescribe transdermal estradiol to influence mood in perimenopausal women experiencing depressive symptoms,” says Dr. JoAnn Pinkerton, NAMS executive director.”

The North American Menopause Society
www.menopause.org/docs/default-source/default-document-library/transdermal-estradiol-for-depression-10-2-17.pdf
 

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:36:58Transdermal estradiol shows promise in treating and preventing perimenopausal depression

Using machine learning to improve patient care

, 26 August 2020/in E-News /by 3wmedia

Doctors are often deluged by signals from charts, test results, and other metrics to keep track of. It can be difficult to integrate and monitor all of these data for multiple patients while making real-time treatment decisions, especially when data is documented inconsistently across hospitals.
In a new pair of papers, researchers from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) explore ways for computers to help doctors make better medical decisions.
One team created a machine-learning approach called “ICU Intervene” that takes large amounts of intensive-care-unit (ICU) data, from vitals and labs to notes and demographics, to determine what kinds of treatments are needed for different symptoms. The system uses “deep learning” to make real-time predictions, learning from past ICU cases to make suggestions for critical care, while also explaining the reasoning behind these decisions.
“The system could potentially be an aid for doctors in the ICU, which is a high-stress, high-demand environment,” says PhD student Harini Suresh, lead author on the paper about ICU Intervene. “The goal is to leverage data from medical records to improve health care and predict actionable interventions.”
Another team developed an approach called “EHR Model Transfer” that can facilitate the application of predictive models on an electronic health record (EHR) system, despite being trained on data from a different EHR system. Specifically, using this approach the team showed that predictive models for mortality and prolonged length of stay can be trained on one EHR system and used to make predictions in another.
ICU Intervene was co-developed by Suresh, undergraduate student Nathan Hunt, postdoc Alistair Johnson, researcher Leo Anthony Celi, MIT Professor Peter Szolovits, and PhD student Marzyeh Ghassemi. It was presented this month at the Machine Learning for Healthcare Conference in Boston.
EHR Model Transfer was co-developed by lead authors Jen Gong and Tristan Naumann, both PhD students at CSAIL, as well as Szolovits and John Guttag, who is the Dugald C. Jackson Professor in Electrical Engineering. It was presented at the ACM’s Special Interest Group on Knowledge Discovery and Data Mining in Halifax, Canada.
Both models were trained using data from the critical care database MIMIC, which includes de-identified data from roughly 40,000 critical care patients and was developed by the MIT Lab for Computational Physiology.


MIT CSAIL
www.csail.mit.edu/using_machine_learning_to_improve_patient_care%20

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:37:06Using machine learning to improve patient care

Sphere Medical confirms compatibility of bedside blood gas monitoring system with leading global monitoring company

, 26 August 2020/in E-News /by 3wmedia

Sphere Medical, an innovative company in critical care monitoring and diagnostics equipment, announces that its Proxima™ bedside blood gas monitoring system is compatible with Philips IntelliVue Patient Monitoring Systems through the Philips IntelliBridge Interface Module.
Sphere Medical’s Proxima is an acute respiratory and metabolic monitoring system used in critical care settings which supports proactive patient care, particularly at critical times.  It enables rapid and frequent blood gas, glucose and electrolyte measurements directly at the bedside without the caregiver leaving the patient. Philips compatibility means that Proxima’s results can be recorded and displayed alongside other critical monitoring information, such as blood pressure, ECG, EEG, respiratory rate, cardiac output and temperature. Such consolidated information gives a comprehensive patient overview, enhancing patient management. With the increasing adoption of electronic data record systems in critical care settings, Philips compatibility will also give Proxima customers a very simple means of integrating their data into electronic medical record systems (EMR).
Commenting on the additional point-of-care connectivity functionality of the Proxima bedside blood gas analyser, Wolfgang Rencken, CEO of Sphere Medical said, “We are extremely pleased with the confirmation that Proxima is compatible with Philips IntelliVue patient monitors through the Philips IntelliBridge EC10 medical device interfacing module. Many of our customers use Philips monitoring and data management systems and this connectivity further helps the practical implementation of Proxima as an acute respiratory and metabolic monitoring device in critical care settings.”
www.spheremedical.com

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:442020-08-26 14:36:53Sphere Medical confirms compatibility of bedside blood gas monitoring system with leading global monitoring company
Page 209 of 240«‹207208209210211›»

Latest issue of International Hospital

April 2024

12 December 2025

New imaging framework transforms epilepsy surgery planning

11 December 2025

AI achieves superhuman accuracy in blood cell classification using generative diffusion models

11 December 2025

Siemens Healthineers unveils AI-powered imaging chain

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription